The maximum volume of another administration route, SC injection, is approximately 1.5 mL. Although the safe and effective dose for S-892216 in humans remains uninvestigated, the injectable volume varies depending on the administration route. Thus, we evaluated the effects of different administration routes on PK profiles, specifically comparing SC and IM injections. We conducted a dog PK study using 300 mg of the injectable suspension formulation (Table ) as an estimation for human clinical trials. The drug particle's z-average for the tested suspension was approximately 300 nm. Table and Figure show the results of this study. The developed injectable suspension showed a preferable sustained-release profile in animals up to the size of beagles. Because the PK profiles did not significantly differ between the IM and SC administrations, both the SC and IM administration routes are likely feasible for the S-892216 injectable suspension.